[Efficacy of setegis administration after transvesical adenomectomy].

We studied efficacy ofsetegis in different doses for therapy of lower urinary tract symptoms in patients after transvesical adenomectomy (TVAE). The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE. Compared to the controls, terazosin-treated patients improved urination more noticeably.

[The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia].

The trial enrolled 155 patients (mean age 65 years) with documented benign prostatic hyperplasia and lower urinary tracts symptoms (LUTS) (IPSS > 6). All the patients received permixon in a dose 160 mg twice a day for 2 years. The data on 130 patients eligible for assessment were processed statistically by dynamics of IPSS, quality of life (QOL), index of sexual function (MSF-4), size of the prostate, urodynamic and biological parameters which were estimated in 6 (V6), 12 (V12), 18 (V18) and 24 months (V24).

[The current approach to assessing the degree of risk in performing urological operations].

Upon analysis of all the available classification of urological operative risk the authors conclude that classification proposed by the Moscow Anesthesiology Scientific Society meets current requirements as it allows for the opinion of the surgeon, anesthesiologist and functional diagnosis specialist.

[The intracavernous injection of Edex (prostaglandin E1) in the treatment of erectile impotence in persons in older age groups].

Erectile impotence may be of neuropathic, vascular, psychogenic and hormonal origin or may be caused by their combination. This impotence occurs in up to 10% of sexually active men. The injection of prostaglandin E1 (PGE1) into the penile cavernous bodies results in venous occlusion warranting maximal erection.

[The prognostic significance of determining androgen receptors in prostatic cancer].

The role of androgen receptors (ARs) registration in cytosol tumor fraction has been investigated in 86 new cases of prostatic cancer. The frequency of occurrence and mean ARs levels in the tumor were found dependent on the disease stage and tumor differentiation. Well-differentiated against moderately and poorly differentiated prostatic cancers contain ARs in 73% and 39% of cases, respectively, in concentrations 10-100 fmol/mg protein and 100 fmol/mg protein, respectively.

[The cardiovascular and thromboembolic complications of intravital estrogen therapy in middle-aged and elderly patients with prostatic cancer].

Cardiovascular and thromboembolic complications arising as a result of 1-16-year estrogen therapy were evaluated in 105 prostatic cancer patients. The incidence of the complications was higher in those who had pretreatment cardiological or vascular load. The latter caused death in half of the patients.

[Incidence and nature of metastases of prostatic cancer based on autopsy data].

Pathways of lymphatic and hematogenic spread for prostatic cancer were studied versus tumor stage and patients' age. Metastases into regional lymph nodes were the most frequent, while bony and visceral metastases ranked second and third, respectively. Age-related peculiarities of dissemination were identified.